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Atopic eczema and major cardiovascular
outcomes: A systematic review and
meta-analysis of population-based studies
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Katrina Abuabara, MD, MA, MSCE,e Liam Smeeth, PhD,b Amanda Roberts, BSc,f and Sinead M. Langan, FRCP, PhDb
Brighton, London, and Nottingham, United Kingdom; Ottawa, Ontario, Canada; Herning, Denmark; and San Francisco, Calif
Background: Atopic eczema is a common inflammatory skin
disease. Various inflammatory conditions have been linked to
cardiovascular disease, a major cause of global mortality and
morbidity.
Objective: We sought to systematically review and meta-analyze
population-based studies assessing associations between atopic
eczema and specific cardiovascular outcomes.
Methods: MEDLINE, Embase, and Global Health were
searched from inception to December 2017. We obtained pooled
estimates using random-effects meta-analyses. We used a
multivariate Bayesian meta-regression model to estimate the
slope of effect of increasing atopic eczema severity on
cardiovascular outcomes.
Results: Nineteen relevant studies were included. The effects of
atopic eczema reported in cross-sectional studies were
heterogeneous, with no evidence for pooled associations with
angina, myocardial infarction, heart failure, or stroke. In cohort
studies atopic eczema was associated with increased risk of
myocardial infarction (n 5 4; relative risk [RR], 1.12; 95% CI,
1.00-1.25), stroke (n 5 4; RR, 1.10; 95% CI, 1.03-1.17), ischemic
stroke n 5 4; RR, 1.17; 95% CI, 1.14-1.20), angina (n 5 2; RR,
1.18; 95% CI, 1.13-1.24), and heart failure (n 5 2; RR, 1.26;
95% CI, 1.05-1.51). Prediction intervals were wide for
myocardial infarction and stroke.
The risk of cardiovascular outcomes appeared to increase with
increasing severity (mean RR increase between severity
categories, 1.15; 95% credibility interval, 1.09-1.21; uncertainty
interval, 1.04-1.28).
Conclusion: Significant associations with cardiovascular
outcomes were more common in cohort studies but with
considerable between-study heterogeneity. Increasing atopic
eczema severity was associated with increased risk of
cardiovascular outcomes. Improved awareness among
stakeholders regarding this small but significant association is
warranted. (J Allergy Clin Immunol 2019;nnn:nnn-nnn.)
Key words: Atopic eczema, atopic dermatitis, angina, myocardial
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Atopic eczema (also known as atopic dermatitis1) is an
inflammatory skin disease traditionally considered a disease of
childhood. However, atopic eczema can affect around 10% of
adults,2,3 and its global prevalence has increased.4 Concurrently,
cardiovascular disease (CVD) is a major cause of mortality and
morbidity globally and has been linked to various chronic
inflammatory conditions.5
Increasing evidence supports an association between atopic
eczema and CVD. Mechanistic studies suggest that platelet
dysfunction and decreased fibrinolysis can contribute to increased
clotting in patients with atopic eczema.6,7 The impaired skin
barrier is known to be more susceptible to acute and chronic
local infection, contributing to inflammation. In addition,
treatments used for atopic eczema can increase cardiovascular
risk.8,9
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Abbreviations used
CrI: Credibility interval
CVD: Cardiovascular disease
GRADE: Grading of Recommendations Assessment,
Development and Evaluation
HR: Hazard ratio
IRR: Incidence rate ratio
OR: Odds ratio
PI: Prediction interval
PRISMA: Preferred Reporting Items for Systematic Review and
Meta-Analysis
PROSPERO: Prospective Register of Systematic Reviews
RR: Relative risk
Epidemiologic studies have inconsistently linked atopic
eczema to cardiovascular risk factors and outcomes across
different populations.10-13 Previous systematic reviews have
found an association between atopic eczema and risk factors for
CVD, including increased body mass index14 and childhood
type 1 diabetes15; however, another review concluded that there
was no association between atopic eczema and most
cardiovascular outcomes.16 Of note, this review did not consider
atopic eczema severity.
We conducted a systematic review and meta-analysis of the
associations between adult atopic eczema and adverse
cardiovascular outcomes overall and according to atopic eczema
severity.
METHODS
The protocol of this systematic review was registered before the study’s
start with the International Prospective Register of Systematic Reviews
(PROSPERO; CRD42017060359) and published in full.17 The study is
reported in line with Preferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA).18
Data sources and searches
Comprehensive search strategies were cocreated by a medical professional
and librarian and reviewed by all authors. We used Ovid to searchMEDLINE,
Embase, and Global Health from their dates of inception to December 16,
2017. Embase was searched from 1947, Global Health from 1910, and Ovid
MEDLINE from 1946. Exclusion filters and limits were not applied to
minimize the risk that eligible studies could be inadvertently excluded. The
Ovid MEDLINE search strategy is available to view (see the supplementary
material in this article’s Online Repository at www.jacionline.org). We hand
searched the bibliographies of included studies and contacted experts in the
field for relevant studies. One additional study was unpublished at the time
of the search and coauthored by the reviewers.19
Study selection criteria
Peer-reviewed published studies in any language from any year were
eligible for inclusion. Studies were required to be population based, with an
average age of participants of greater than 18 years. Studies could be cohort,
case–control, or cross-sectional designs. The exposure of interest was atopic
eczema (atopic dermatitis). The comparator was person years without atopic
eczema. Outcomes were major cardiovascular outcomes: angina, myocardial
infarction, coronary revascularization, heart failure, cardiac arrhythmias,
stroke, and cardiovascular death. Studies of localized or other types of eczema,
such as hand eczema and seborrheic or contact dermatitis, were not eligible for
inclusion.
Data extraction and quality assessment
We used an online literature-reviewing data management program
(Covidence) to facilitate collaboration and data extraction between reviewers.
Two reviewers (A.A. and A.M.Y.) independently screened titles and abstracts
in duplicate unblinded. Full-text articles were retrieved where studies fulfilled
inclusion criteria or where there was ambiguity. Disagreement was resolved
through discussion with a third reviewer (S.M.L.), where necessary. A.A. and
A.M.Y. extracted data independently and in duplicate to minimize bias and
errors using a standardized data extraction tool that was piloted on the first 3
eligible texts.
Additional information was requested from authors by e-mail, where
needed. A full list of data extracted can be found in the supplementarymaterial
in this article’s Online Repository at www.jacionline.org. Principal summary
measures included odds ratios (ORs), hazard ratios (HRs), and incidence rate
ratios (IRRs; all measures of relative risk [RR]).
We grouped studies by the cardiovascular outcome under study and
synthesized them narratively. All studies were of sufficient quality for
inclusion in the narrative synthesis. We only considered information on the
interaction between atopic eczema and covariates if it was formally assessed in
the original publication. Study outcomes considered sufficiently
homogeneous and without a high risk of bias were eligible for inclusion in
meta-analyses to obtain pooled effect estimates.
We compared RR estimates for the relationship between atopic eczema and
cardiovascular outcomes between studies. We used estimates that were
adjusted for confounders, where available. If fully adjusted estimates were
unavailable for a particular study, we used minimally adjusted (age and sex)
estimates instead, or if both of these were unavailable, we used fully adjusted
estimates that were additionally adjusted for possiblemediators (factors on the
causal pathway of CVD, such as smoking, body mass index, hyperlipidemia,
hypertension, depression, anxiety, diabetes, and/or alcohol). The definition of
adjustment differed between studies (see Table E6 in this article’s Online
Repository at www.jacionline.org).
Risk of bias was assessed by using the Newcastle Ottawa Scale
(see Table E4 in this article’s Online Repository at www.jacionline.org) and
a modified Cochrane Collaboration Grading of Recommendations
Assessment, Development and Evaluation (GRADE) tool (see Table E5 in
this article’s Online Repository at www.jacionline.org).
Statistical analysis
Atopic eczema overall. Associations from longitudinal cohort
studies and cross-sectional studies were analyzed separately. For
cross-sectional studies, we displayed the extracted ORs of angina, heart
failure, myocardial infarction, and stroke (separately) for participants with
atopic eczema compared with participants without atopic eczema in forest
plots.We used a random-effectsmeta-analysis model with the inverse variance
method of DerSimonian and Laird20 to estimate between-study (population)
heterogeneity and the I2 measure21 to quantify the proportion of total variance
attributable to this heterogeneity. We present the 95% CI for the pooled
estimates, as well as a 95% prediction interval (PI).22 Because the CI can
convey spurious precision in the presence of population heterogeneity, we
interpret the PIs to address our research question. PIs were not calculated
for analyses of fewer than 4 studies.
We performed a similar analysis in longitudinal cohort studies, pooling log
HRs, log IRRs, or both in the meta-analysis.
Atopic eczema severity. All studies assessing the relationship
between atopic eczema severity and cardiovascular outcomes were cohorts,
with the exception of 2 cross-sectional studies (see Table E3 in this article’s
Online Repository at www.jacionline.org). We excluded these10,23 and
displayed the rest in a graph of the (log) HR or IRR against atopic eczema
severity (mild, moderate, or severe).
To estimate the relative increase in risk attributable to severity, we
constructed a multivariate linear mixed model relating log HRs (IRRs) for
each of the 6 outcomes to atopic eczema severity. The linear predictor
consisted of an outcome-specific fixed intercept, a random study intercept, an
outcome-specific fixed slope for severity (assuming linearity), and random
error. We performed a Bayesian analysis on this model with uninformative
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‘‘priors’’ (assumptions about the value of unknown parameters that affect
estimation), except for the precision of the observed logHRs (IRRs), whichwe
gave the informative priors of the inverse of their observed variance.We report
the means and 2.5 and 97.5 quantiles of the posterior distributions, which are
the pooled estimates, and their 95% credibility intervals (CrI; analogous to the
95% CI for the mean). We used a Bayesian instead of a frequentist method
because correct inference can be achieved with smaller samples than are
necessary for frequentist mixed-effects models.24
We performed a secondary analysis to estimate the generalized increase in
risk attributable to atopic eczema severity. Using a similar model, we changed
the fixed outcome intercept to a random intercept and the fixed outcome slopes
to a single fixed slope with a random slope effect. The variance of the random
slope estimates the between-outcomevariability in risk increase and can be used
to estimate the distribution of risk increase across all cardiovascular outcomes.
In addition to themeasures above,we report the 95%uncertainty interval, which
is analogous to the 95% PI, by summing the slope and its estimated random
effect and reporting the 2.5 and 97.5 quantiles of this posterior distribution. The
code for both models is available in the supplementary material in this article’s
Online Repository at www.jacionline.org. All statistical analyses were
performed in R software (version 3.4.3)25 by using the ‘‘meta’’26 and ‘‘rjags’’27
packages. No subgroup analyses were undertaken.
RESULTS
We screened 5435 records after deduplication, assessing 44 full
texts and finding 16 relevant articles reporting 19 different
studies, 17 of which were synthesized in the meta-analyses. All
relevant studies were available in English. See Fig 1 for the
PRISMA flow chart detailing the process of study selection,
including reasons for exclusion.
Study characteristics
Table E1 in this article’s Online Repository at www.jacionline.
org details the characteristics of studies matching eligibility criteria.
FIG 1. PRISMA flow chart: results of the search strategy.
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Eight studies were longitudinal cohort studies,10-12,19,28-31 1 was a
very restricted cohort study described as a case-control study,32
and 10 were cross-sectional studies (reported in 8 articles).10,23,33-38
Population sizes in individual studies ranged from 4,970 subjects to
72,651,487 total population. Stroke and myocardial infarction were
the most common cardiovascular outcomes under study. Seven
studies assessed the risk of cardiovascular outcomes by atopic
eczema severity, with 6 of these studies defining atopic eczema
severity by use of systemic treatments10,12,19,23,28 and 1 study using
number of dermatology visits as a proxy for severity.11 Data for
our other secondary objectives, including effect modification by
sex or the possible role of treatments in cardiovascular risk, were
largely unavailable.
Risk of bias within studies
Tables E4 and E5 provide details of study quality based on the
Newcastle Ottawa Scale and GRADE. Our GRADE assessments
of each outcome were of either low or very low quality of
evidence to support these associations. Although no outcomes
were at high risk of bias, the association estimates, definitions
of exposure, outcomes, and populations were heterogeneous,
and CIs were wide.
Results of individual studies
Table E2 in this article’s Online Repository at www.jacionline.
org details the main reported results of included studies. Two
studies were excluded from the quantitative meta-analysis
because their outcomes under studywere not specifically focused.
Marshall et al32 found no significant association between atopic
eczema and their composite outcome of several CVDs (OR,
1.032; 95% CI, 0.744-1.432; P 5 .8489), whereas Radtke
et al36 found a significantly lower unadjusted prevalence ratio
of ischemic heart disease (OR, 0.83; 95% CI, 0.80-0.86) in those
with atopic eczema compared with those without.
Results of meta-analyses
Association between atopic eczema and the risk of
CVD outcomes. Cross-sectional studies. Three
cross-sectional studies estimated the association between atopic
eczema overall and angina, with an average OR of 1.78 (95% CI,
1.44-2.20) and 95% PI of 0.45 to 7.03. For heart failure, the
average OR between 2 studies was 1.32 (95% CI, 0.70-2.48). The
95% PI was not estimated because there were too few studies.
Eight cross-sectional studies provided estimates for the
association between atopic eczema and each of myocardial
infarction and stroke. For both outcomes, there was substantial
heterogeneity between studies (I2, 97% and 96%, respectively)
and no evidence that the average OR was different from 1, with
wide PIs (myocardial infarction: OR, 1.04; 95% PI, 0.27-4.10;
stroke: OR, 1.18; 95% PI, 0.35-3.89). Wide PIs for all outcomes
from cross-sectional studies suggested a wide range of population
effects, some of whichmight associate having atopic eczemawith
lower odds and some with higher odds of having a myocardial
infarction or stroke; however, cohort studies were more
homogeneous than cross-sectional studies and had more
consistent estimates. All forest plots for cross-sectional studies
are shown in Fig 2.
Longitudinal cohort studies. Cohort studies were of more
interest for their ability to demonstrate temporality. Forest plots
for cohort studies are shown in Fig 3. Few studies provided
estimates for the effect of atopic eczema on the risk of angina,
heart failure, and cardiovascular death. The average RR for
angina (n 5 2) was estimated to be 1.18 (95% CI, 1.13-1.24),
and that for heart failure (n 5 2) was estimated to be 1.26 (95%
CI, 1.05-1.51). PIs were not estimable. The only study to
report an effect of atopic eczema on cardiovascular death19
provided no evidence of an association (HR, 0.98; 95% CI,
0.91-1.05).
Four longitudinal cohort studies provided estimates for the
effect of atopic eczema and each of the risk of stroke, ischemic
stroke, and myocardial infarction. There was evidence that both
the average effect and the distribution of population effects
supported an increased risk of ischemic stroke (average RR, 1.17;
95%CI, 1.14-1.20; 95% PI, 1.10-1.24). For myocardial infarction
and stroke, therewas evidence that the average association was an
increase in risk but not across the entire population distribution, as
indicated by 95%CIs of greater than 1 but 95% PIs that spanned 1
(myocardial infarction: average RR, 1.12; 95% CI, 1.00-1.25;
95% PI, 0.73-1.70; stroke: average RR, 1.10; 95% CI, 1.03-1.17;
95% PI, 0.83-1.45).
Association between atopic eczema severity and
risk of CVD outcomes. The risk of having all 6 outcomes
appeared to increase with increasing atopic eczema severity, and
the slope of this relationship appeared very similar between
studies and outcomes (Fig 4, A). All 6 slopes estimated from the
multivariate Bayesian model were positive, supporting this
association (Fig 4, B).
Atopic eczema severity was associated with an increased risk
of angina (n5 2; RR per-unit increase in severity, 1.16; 95% CrI,
1.07-1.26), heart failure (n 5 1; RR, 1.20; 95% CrI, 1.06-1.36),
cardiovascular death (n 5 2; RR, 1.25; 95% CrI, 1.13-1.38), and
myocardial infarction (n 5 3; RR, 1.14; 95% CrI, 1.05-1.23) in
patients with atopic eczema. There was no statistically significant
evidence for the association with stroke (n 5 2; RR, 1.07; 95%
CrI, 0.99-1.15) or ischemic stroke (n 5 2; RR, 1.17; 95% CrI,
0.98-1.39).
The mean RR increase in having any of the prespecified
cardiovascular outcomes was 1.15 (95% CrI, 1.09-1.21) with
increasing severity categories (eg, mild to moderate or moderate
to severe). The uncertainty interval within which we expect to find
95% of all RRs was 1.04 to 1.28, providing evidence for an
association in patients with atopic eczema between severity of
disease and an increased risk of CVD.
We have not formally explored causes of heterogeneity because
the low number of studies for these outcomes provides little
power to detect them. We could not explore publication bias with
funnel plots because in the presence of high heterogeneity, there is
no reason to expect a plot of estimates against their SEs to have a
funnel shape.39
FIG 2. Forest plots of cross-sectional studies estimating the association between atopic eczema and angina,
heart failure, myocardial infarction, and stroke. Box sizes are proportional to study weighting in the
random-effects meta-analysis, where larger boxes indicate greater precision.NHANES, National Health and
Nutrition Examination Survey; NHIS, National Health Interview Survey.
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DISCUSSION
Our systematic review and meta-analysis found an association
with stroke and myocardial infarction in cohort studies and an
association with increasing disease severity across all cardiovascular
outcomes under study. High heterogeneity and imprecision resulted
in low quality of evidence to support these associations; however, all
outcomes were judged to be of low risk of bias.
Strengths and limitations
The strengths of our study include our preregistered and
published protocol, increasing the transparency of our study.
A librarian and medical professional coplanned a systematic and
broad search strategy attempting to identify all studies meeting
eligibility criteria. Two authors (A.A. and A.M.Y.) independently
assessed search results by using an online data management
program to minimize bias and errors in screening, data extraction,
and quality assessment of studies. This is the first systematic
review and meta-analysis (to our knowledge) to review the
association between CVD and atopic eczema severity. We
directly addressed uncertainties in observational data by
calculating credibility and PIs where enough studies were
returned for the association between atopic eczema and
cardiovascular outcomes. PRISMA guidelines informed the
reporting of this systematic review.40
It is still possible that relevant articles might have been missed,
despite an extensive search. Some of our conclusions are limited
by a lack of systematic reporting of outcomes, heterogeneity in
the definitions of atopic eczema and atopic eczema severity, and
adjustment models used in included studies. The statistical
methods address some of these limitations with the calculation
of PIs. Some outcomes with 2 studies could not estimate a PI, and
thosewith 3 or 4 studies had a not well-estimated PI; however, the
results for outcomes with more data available were robust.
Limited sensitivity analyses could be undertaken because of the
small of numbers of studies returned, and some of the questions
we set out to answer could not be answered because of an absence
of evidence. Between-study heterogeneity and corresponding
statistics are not well estimated from a small number of studies,
which is reflected in our GRADE assessments of low-quality
evidence, making it difficult to draw firm conclusions from this
review.41 Publication bias could not be formally assessed because
of the presence of high heterogeneity and small study numbers.
Comparison with previous studies
A previous systematic review reported no significant
association between atopic eczema and myocardial infarction
and stroke.16 However, this review pooled crude estimates
preferentially, meta-analyzed the associations from
cross-sectional and longitudinal cohort studies together, and
included fewer relevant studies. In addition, this previous review
did not address atopic eczema severity.
Although individual studies have come to varied conclusions
on the association between atopic eczema and cardiovascular
outcomes, systematic reviews have contributed to the evidence
that atopic eczema is associated with an increased prevalence of
certain mediators on the causal pathway to CVD. Zhang et al14
found an increased prevalence of obesity in North America and
Asia, whereas smoking,42 depression, anxiety, hyperlipidemia,
and hypertension have all been associated with atopic eczema.
Meta-analyses have not shown evidence for increased alcohol
use43 or type 2 diabetes.16 Other atopic diseases, such as asthma,
have also been linked to increased cardiovascular outcomes.44
Silverwood et al19 adjusted for mediators, including increased
body mass index, smoking, severe alcohol use, hyperlipidemia,
hypertension, diabetes, depression, and anxiety, and still found
a positive association between unstable angina and heart failure
and atopic eczema (overall). Standl et al10 found no association
between a number of genetic risk factors for CVD and atopic
eczema. Alternative explanations contributing to an increase in
risk factors could be behavioral factors linked to the burden of
disease, such as reduction of physical activity caused by discom-
fort, and the established link between inflammation and CVD.
Our results in context
Although we found no association overall between atopic
eczema and cardiovascular outcomes, the association between
FIG 3. Forest plots of longitudinal cohort studies estimating the association between atopic eczema and the
risk of angina, heart failure, myocardial infarction, stroke, or ischemic stroke. Box sizes are proportional to
study weighting in the random-effects meta-analysis, where larger boxes indicate greater precision.
=
FIG 4. RR of cardiovascular outcomes (compared with subjects without
atopic eczema) plotted against atopic eczema severity. A, Observed
associations with CIs in each study and lines connecting within-study
estimates. B, Estimated relative increase in risk (ie, slope) for each outcome
with 95% CrIs. CV, Cardiovascular; MI, myocardial infarction.
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increasing atopic eczema severity and cardiovascular outcomes
appeared consistent across the small number of included studies.
Further studies would have been desirable. The determination of
absolute risks was beyond the scope of this review, but
Silverwood et al19 did highlight that absolute risks can remain
low, even in the context of high RRs.
The question remains whether there is a causal link between
atopic eczema and CVD. The link between psoriasis and CVD is
now established; however, the 2 diseases have distinct
immunoprofiles, with a TH2 signal predominating in patients
with psoriasis and TH1 signal persisting in patients with chronic
atopic eczema.45 Factors supporting a causal link between
atopic eczema and cardiovascular outcomes include
mechanistic theories linking inflammation and CVD, the
evidence for temporality, and the evidence for a
dose-response relationship between atopic eczema severity
and cardiovascular outcomes.
Challenges remain because of the types of data used to
answer this question. Only 1 study defined atopic eczema
severity as a time-updated variable.19 Therefore there might
have been misclassification of severity, leading to over-
estimating or underestimating the risk associated with mild
or moderate disease. In addition, childhood-onset compared
with adult-onset atopic eczema was poorly reported in the
literature but could potentially be a significant issue.
Misclassification bias could account for an increased risk of
cardiovascular outcomes in patients with atopic eczema
because those with severe disease are often defined by
receiving systemic therapies, although for most of the
outcomes studies, this is not likely to be a particular issue
because we have focused on major cardiovascular outcomes
that are likely to present for care.
The study by Sung et al29 was the only study in this review to
disregard treatment while defining atopic eczema severity by
using number of dermatology visits as a proxy for severity.
A dose response remained between increasing numbers of
dermatologic visits and increasing risk of ischemic stroke.
Increased health care consumption could increase the likelihood
of picking up alternative diagnoses, such as atrial fibrillation;
however, this is unlikely to account for all of the associations
seen.
Silverwood et al19 undertook sensitivity analyses adjusting for
high-dose oral glucocorticoid use by removing patients treated
with cyclosporine or methotrexate; however, none of these
approaches significantly affected their finding that moderate-to-
severe atopic eczema was associated with an increased risk of
specific CVD outcomes, suggesting that the association persisted
independent of systemic treatment type. It is possible that some
systemic therapies can protect against CVD. In patients with
psoriasis, methotrexate therapy might be protective against
cardiovascular outcomes; however, glucocorticoids and
cyclosporine could increase cardiovascular risk through
hypertension and hyperlipidemia.
It would be beneficial for future studies to separate confounders
and then subsequently adjust for both confounders and mediators
to address the important question of whether the inflammatory
burden of atopic eczema contributes to CVD independently. This
would aid delineation of the contribution of increased burden of
cardiovascular risk factors and increased risk of CVD conferred
by the disease itself.
Conclusion
This study is the first to meta-analyze the association
between increasing atopic eczema disease severity and
cardiovascular outcomes, demonstrating evidence of a dose-
response relationship between increasing severity and
cardiovascular outcomes. Further studies are required to
understand the basis of this finding to support targeted prevention
strategies for those with moderate-to-severe atopic eczema.
Clinical implications: Understanding the basis of the dose-
response relationship between atopic eczema disease severity
and cardiovascular outcomes is key to supporting targeted
prevention strategies for those with moderate-to-severe atopic
eczema.
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